NBTX Earnings Date: Apr 27, 2027 (Estimated) — Nanobiotix S.A.
NASDAQ · Healthcare · Biotechnology
Updated
When is NBTX's next earnings date?
Nanobiotix S.A. (NBTX) is expected to report FY 2026 earnings on Tuesday, April 27, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.16 on revenue of $76.9M.
How did NBTX do in its last earnings report?
In its most recent report on Sep 29, 2026, Nanobiotix S.A. posted EPS of -$0.80 versus the -$0.48 estimate, a miss of 64.7%. Revenue was $6.4M against a $1.7M estimate. The stock's 1-day post-earnings move was -4.4%.
How much does NBTX stock move after earnings?
NBTX beat EPS estimates in 0 of its last 2 reported quarters. Over the last 8 reports the stock moved an average of 3.3% (up or down) in the day after earnings.
About Nanobiotix S.A.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-29 | -0.48 | -0.80 | -64.70% | $6.4M | ❌ Miss | -4.42% | -23.01% | +5.92% | |
| 2026-09-24 | H1 2026 | — | -0.82 | — | $6.5M | — | -0.45% | -16.62% | -12.25% |
| 2026-03-31 | FY 2025 | — | -0.58 | — | $37.9M | ❌ Miss | +10.37% | -0.19% | +12.15% |
| 2025-09-30 | H1 2025 | — | -0.12 | — | $30.2M | — | -0.79% | +11.01% | -4.76% |
| 2025-04-02 | FY 2024 | — | 1.56 | — | $13.1M | — | -0.59% | -6.76% | -1.74% |
| 2024-09-18 | H1 2024 | — | -0.50 | — | $10.0M | — | +7.91% | -0.20% | -4.46% |
| 2024-04-24 | FY 2023 | — | -1.17 | — | $39.3M | — | +0.17% | +1.69% | +12.03% |
| 2023-09-26 | H1 2023 | — | -0.87 | — | $3.6M | — | -1.52% | +5.10% | -24.06% |
Showing last 8 quarters.